Printer Friendly

Hemispherx Biopharma extends contract with Armada Health Care.

M2 PHARMA-August 19, 2015-Hemispherx Biopharma extends contract with Armada Health Care


United States-based Hemispherx Biopharma has extended its contract with Armada Health Care for two years.

It was reported yesterday that the agreement has been signed for the sales/marketing of Alferon N Injection, its Food and Drug Administration approved natural interferon, in the United States. According to the contract, the firm will produce and supply Alferon N Injection to physicians and patients through Armada's national network of specialty pharmacies.

Armada Health Care has agreed to provide ongoing sales and marketing to support the product's re-launch. Specialty Distributor, BioRidge Pharma (BRP), has received a two-year contract extension and will warehouse, ship, and distribute Alferon N Injection on an exclusive basis for United States sales.

((Comments on this story may be sent to

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Aug 19, 2015
Previous Article:DelMar Pharmaceuticals receives increased funding from National Research Council of Canada Industrial Research Assistance Program.
Next Article:Alexion Pharma Canada receives approval for Strensiq from Health Canada.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters